Tradename to be confirmed Vertex Pharmaceuticals Australia Pty Ltd
Product name
Tradename to be confirmed
Accepted date
Sep-2024
Active ingredients
deutivacaftor, tezacaftor, vanzacaftor
Proposed indication
Treatment of cystic fibrosis in people aged 6 years and older who have at least one responsive mutation in the cystic fibrosis gene (CFTR).
Application type
B (new combination)
Publication date
Sep-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.